Skip to main content
No access
Clinical and Research Reports
Published Online: 20 November 2023

Psychiatric Screening Measures in Behavioral Variant Frontotemporal Dementia

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

Abstract

Objective:

Behavioral variant frontotemporal dementia (bvFTD) is sometimes misdiagnosed as a primary psychiatric disorder, such as major depressive disorder, bipolar disorder, an anxiety disorder, autism spectrum disorder (ASD), or attention-deficit hyperactivity disorder (ADHD). Nonspecialists often use screening measures for primary psychiatric disorders in early assessments of persons with bvFTD. The investigators aimed to evaluate the manifestations of bvFTD in surveys intended to screen for primary psychiatric disorders.

Methods:

Patients with bvFTD (N=27) presenting to an academic neurobehavior specialty clinic and their caregivers were provided questionnaire packets including the Mood Disorder Questionnaire (MDQ), the Patient Health Questionnaire–9 (PHQ-9), the Generalized Anxiety Disorder–7 scale (GAD-7), the Adult ADHD Self-Report Scale, version 1.1, the Ritvo Autism and Asperger Diagnostic Scale, and the Neuropsychiatric Inventory Questionnaire. Established cutoff scores suggesting the presence of a primary psychiatric disorder were used to define a “positive” response. Individual questions from each screening questionnaire were examined for a more granular characterization of bvFTD.

Results:

Overall, 15% of bvFTD patients screened positive for bipolar disorder, 54% screened positive for ADHD, and 89% screened positive for ASD. Hyperactivity or hypersensitivity symptoms were infrequently endorsed. In addition, 57% of respondents screened positive for depressive symptoms on the PHQ-9, and 43% screened positive for anxiety symptoms on the GAD-7.

Conclusions:

The use of cutoff scores on screening measures for primary psychiatric disorders resulted in potentially problematic positive screens of primary psychiatric disorders among persons with bvFTD. Identifying specific questions that distinguish between bvFTD and primary psychiatric disorders requires further study.

Get full access to this content

View all available purchase options and get full access to this content.

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 160 - 165
PubMed: 37981780

History

Received: 2 March 2023
Revision received: 19 July 2023
Revision received: 25 July 2023
Accepted: 17 August 2023
Published online: 20 November 2023
Published in print: Spring 2024

Keywords

  1. Behavioral Variant Frontotemporal Dementia
  2. Dementia
  3. Frontotemporal Dementia
  4. Primary Psychiatric Disorders
  5. Psychiatric Diagnoses
  6. Psychiatric Screening

Authors

Details

Peter S. Pressman, M.D. [email protected]
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).
Joie Molden, Ph.D.
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).
Hal S. Wortzel, M.D.
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).
Evan Plys, Ph.D.
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).
Jonathan H. Woodcock, M.D.
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).
Christopher M. Filley, M.D.
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).
David B. Arciniegas, M.D.
Behavioral Neurology Section, Department of Neurology (Pressman, Wortzel, Woodcock, Filley, Arciniegas), and Department of Psychiatry (Wortzel, Filley, Arciniegas), University of Colorado School of Medicine, Aurora; Departments of Neurosurgery (Molden) and Psychiatry (Plys) and the Marcus Institute for Brain Health (Filley, Arciniegas), University of Colorado Anschutz Medical Campus, Aurora; Rocky Mountain Mental Illness Research, Education, and Clinical Center for Suicide Prevention, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora (Wortzel); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Arciniegas).

Notes

Send correspondence to Dr. Pressman ([email protected]).
This work was presented in part at the 31st annual meeting of the American Neuropsychiatric Association, held virtually, March 17–21, 2021.

Competing Interests

The authors report no financial relationships with commercial interests. Dr. Arciniegas is Editor of the journal; Consulting Editor David A. Silbersweig, M.D., served as decision editor during peer review of the manuscript.

Funding Information

Supported by the National Institute on Aging (grant K23AG063900 and an administrative supplement), the Colorado Clinical and Translational Sciences Institute, and the Doris Duke Fund to Retain Clinical Scientists program.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share